Oric Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing medicines to fight drug-resistant cancers. Its two lead drugs are rinzimetostat, a pill for advanced prostate cancer, and enozertinib, a brain-penetrating treatment for certain lung cancers, with trials run alongside partners Johnson & Johnson and Bayer. The company was founded in 2014 by top cancer researchers, and its name is an acronym for "Overcoming Resistance In Cancer."
Granted 189.3K · Sold 402.6K
Granted 32.8K · Sold 6.7K
Granted 130.4K · Sold 147.9K
Granted 84.2K
Granted 67.4K · Sold 24.9K
Bought 28.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Chacko JacobPRESIDENT AND CEO, Director · 13 transactions | -25.5% | 581.7K | 189.3K | — | 402.6K |
| Heyman Richard A.Director · 4 transactions | +11.4% | 254.9K | 32.8K | — | 6.7K |
| Piscitelli DominicChief Financial Officer · 20 transactions | +78.6% | 120.1K | 130.4K | — | 147.9K |
| Kunkel Lori AnneDirector · 5 transactions | — | 84.2K | 84.2K | — | — |
| Multani Pratik SChief Medical Officer · 6 transactions | +835.5% | 68.1K | 67.4K | — | 24.9K |
| You AngieDirector · 2 transactions | — | 28.0Kas of Jun 2025 | — | 28.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -554.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.